One of the first Alzheimer’s drugs capable of slowing the disease’s progression should not be given to the majority of patients due to safety concerns, a study suggests.Research appears to show that the drug, lecanemab, can slow the degenerative brain condition by a third. And last month, US health regulators approved the twice-monthly injection for patients with mild cognitive impairment or mild dementia – meaning the Alzheimer’s is in its earliest stages.The spending watchdog is due to begin assessing the drug for use in the UK next month, hoping that it could help the one million Alzheimer’s sufferers in the UK.
Load More
Load More